Acid-promoted palladium(II)-catalyzed ortho-halogenation of primary benzamides: En route to halo-arenes
作者:Yogesh Jaiswal、Amit Kumar
DOI:10.1016/j.catcom.2019.105784
日期:2019.11
Brønsted acid-promoted palladium(II)-catalyzed regioselective installation of halogens (Br, Cl, and I) to the aromatic ring of benzamide derivatives has been achieved using primary amides. A wide variety of benzamides were compatible under established conditions to afford the halogenated products without installing any external auxiliary. Mild reaction conditions, use of primary amide as a directing
[EN] PYRROLO[2,3-B]PYRIDINE CDK9 KINASE INHIBITORS<br/>[FR] INHIBITEURS DE PYRROLO[2,3-B]PYRIDINE CDK9 KINASE
申请人:ABBVIE INC
公开号:WO2014139328A1
公开(公告)日:2014-09-18
Disclosed are compounds of Formula (IIa), wherein R1, R2, R3A, R3B, R3C, R3D, R3E, and R4 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds may be used as agents in the treatment of diseases, including cancer. Also provided are pharmaceutical compositions comprising one or more compounds of Formula (IIa).
Nickel-catalyzed regioselective C–H halogenation of electron-deficient arenes
作者:Ze-Lin Li、Peng-Yu Wu、Chun Cai
DOI:10.1039/c8nj06023a
日期:——
the ortho-halogenation of electron-deficient arenes with easily available halogenating reagents N-halosuccinimides (NXS; X = Br, Cl and I). The transformation was highly regioselective and a wide substrate scope and functional group tolerance were observed. This discovery could be of great significance for the selective halogenation of amides, benzoic esters and other substances with guiding groups. Mechanistic
开发了一种简单的Ni(II)催化的一般策略,用于用易获得的卤化试剂N-卤代琥珀酰亚胺(NXS; X = Br,Cl和I)对电子缺陷型芳烃进行邻卤代化。该转化是高度区域选择性的,并且观察到宽的底物范围和官能团耐受性。该发现对于酰胺,苯甲酸酯和其他具有引导基团的物质的选择性卤化可能具有重要意义。还介绍了机械研究。
[EN] HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS<br/>[FR] AGENTS CHIMIOTHÉRAPEUTIQUES À BASE D'ÉTHER MACROCYCLIQUE HÉTÉROAROMATIQUE
申请人:NUVALENT INC
公开号:WO2021226269A1
公开(公告)日:2021-11-11
Disclosed are heterocyclic heteroaromatic macrocyclic ether compounds, pharmaceutically acceptable salts of the compounds and pharmaceutical compositions thereof. Also disclosed are methods of treating or preventing cancer using the heterocyclic heteroaromatic macrocyclic ether compounds, pharmaceutically acceptable salts of the compounds, and pharmaceutical compositions thereof.
Compounds, compositions and methods for modulating the activity of receptors are provided. In particular compounds and compositions are provided for modulating the activity of receptors and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder directly or indirectly related to the activity of the receptors.